Special Issue "Basic Research of Hepatopancreatobillary Tumor"
Deadline for manuscript submissions: 5 May 2024 | Viewed by 1569
Interests: hepatobiliary and pancreatic tumors
Interests: development and treatment of hepatobiliary and pancreatic malignancies; surgical treatment of malignant tumors of the digestive system; early diagnosis of gallbladder cancer
Interests: the signaling pathway of NF-κB transcription factor and the role of NF-κB in cancer; anti-apoptosis; inflammation and immune response, and the feedback regulation mechanism of NF-κB and IκBα
We are pleased to invite you or your promising young colleagues to make a valuable contribution to the Special Issue of Cancers titled “Basic research on Hepatopancreatobillary Tumors”.
Over the past several decades, primary liver cancer (PLC), pancreatic cancer, and gallbladder cancer have become the focus of rising concern mainly due to the increasing rates of incidence and high global mortality. Anatomically, the primary sites of these three types of cancer are adjacent to each other. However, the mechanisms of these tumors’ development are different. A number of mechanisms have been shown to be involved in tumorigenesis, tumor development, and tumor metastasis. Today, the tumor microenvironment appears to be highly involved in the tumor pathological condition and poor prognosis. There has been no major breakthrough in drug treatment for hepatopancreatobillary tumor in recent 10 years. Recently, diversity and heterogeneity in the tumor microenvironment have attracted attention. New technology developments bring more opportunities for scientists to understand tumor heterogeneity and new therapy. After resolving the immune microenvironment within the tumor, targeted therapy and immunotherapy become more promising. However, after the application of targeted therapy and immunotherapy, hepatobiliary and pancreatic tumors quickly develop drug resistance. The underlying drug resistance and immune escape mechanisms of tumors also need to be urgently investigated.
To summarize, we focus on basic research in hepatobiliary and pancreatic tumors. This Special Issue aims to bring together current findings and opinions in many aspects of the hepatopancreatobillary tumor to provide clues for tumorigenesis, tumor development, tumor metastasis, and tumor therapy in this field.
Original research articles and reviews are welcome in this Special Issue. We aim to study the mechanisms of hepatopancreatobillary tumors. Research areas may include (but are not limited to) the following: tumorigenesis, tumor proliferation, tumor therapy target, tumor drug resistance, tumor metabolism, and the tumor immune microenvironment.
We look forward to receiving your contributions.
Prof. Dr. Lianxin Liu
Prof. Dr. Yingbin Liu
Prof. Dr. Paul J. Chiao
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- liver cancer
- gallbladder cancer
- pancreatic cancer
- drug resistant